- Home
- LGL vs BRNS Comparison
LGL vs BRNS Comparison
Compare LGL & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGL
- BRNS
- Stock Information
- Founded
- LGL 1917
- BRNS 2016
- Country
- LGL United States
- BRNS United Kingdom
- Employees
- LGL N/A
- BRNS N/A
- Industry
- LGL Industrial Machinery/Components
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- LGL Technology
- BRNS Health Care
- Exchange
- LGL Nasdaq
- BRNS Nasdaq
- Market Cap
- LGL 37.5M
- BRNS 38.7M
- IPO Year
- LGL N/A
- BRNS 2021
- Fundamental
- Price
- LGL $6.40
- BRNS $0.89
- Analyst Decision
- LGL
- BRNS Strong Buy
- Analyst Count
- LGL 0
- BRNS 2
- Target Price
- LGL N/A
- BRNS $3.00
- AVG Volume (30 Days)
- LGL 5.8K
- BRNS 33.9K
- Earning Date
- LGL 05-23-2025
- BRNS 05-07-2025
- Dividend Yield
- LGL N/A
- BRNS N/A
- EPS Growth
- LGL 59.20
- BRNS N/A
- EPS
- LGL 0.08
- BRNS N/A
- Revenue
- LGL $4,292,000.00
- BRNS $14,969,000.00
- Revenue This Year
- LGL N/A
- BRNS N/A
- Revenue Next Year
- LGL N/A
- BRNS N/A
- P/E Ratio
- LGL $85.81
- BRNS N/A
- Revenue Growth
- LGL 16.69
- BRNS 4381.74
- 52 Week Low
- LGL $4.86
- BRNS $0.64
- 52 Week High
- LGL $7.28
- BRNS $2.45
- Technical
- Relative Strength Index (RSI)
- LGL 45.18
- BRNS 49.53
- Support Level
- LGL $6.12
- BRNS $0.80
- Resistance Level
- LGL $6.87
- BRNS $0.95
- Average True Range (ATR)
- LGL 0.19
- BRNS 0.11
- MACD
- LGL -0.05
- BRNS -0.00
- Stochastic Oscillator
- LGL 29.17
- BRNS 35.14
About LGL LGL Group Inc. (The)
LGL Group Inc is a holding company engaged in services, merchant investment and manufacturing business activities. The company has two reportable segments; Electronic Instruments and Merchant Investment. The Electronic Instruments segment, which generates key revenue, is focused on designing and manufacturing high-performance Frequency and Time reference standards that form the basis for timing and synchronization in various applications including satellite communication, time transfer systems, network synchronization, electricity distribution, and metrology. The Merchant Investment segment comprises various investment vehicles in which the company invests its capital.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.